1 / 47

Nosocomial Infections

Nosocomial Infections. Emergence of Antimicrobial Resistance. Mazen Kherallah, MD, FCCP King Faisal Specialist Hospital & Research Center. Impact of Antibiotic Restriction on Resistance Neurosurgical Intensive Care Unit in London. All antibiotics stopped.

amber
Download Presentation

Nosocomial Infections

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Nosocomial Infections Emergence of Antimicrobial Resistance Mazen Kherallah, MD, FCCP King Faisal Specialist Hospital & Research Center

  2. Impact of Antibiotic Restriction on ResistanceNeurosurgical Intensive Care Unit in London All antibiotics stopped 1968 1969 1970 Price. Lancet. 1970

  3. Rate of Device-Related Infections in ICU

  4. Decrease in Hospital-acquired ICU Infection Rates, NNIS, 1990-1999

  5. Possible Explanation for Decrease in Infection Rate • Efforts to prevent infections: new research findings, prevention guidelines • Shift of health care from hospital-based care • True decrease secondary to adhesion to infection control policies

  6. Antimicrobial Resistance:A Global Problem • ICAAC 1998 • Antimicrobial Resistance Symposium: 200 attendees • Infectious disease physicians (25%), microbiologist (25%), other physicians, pharmacists, etc. (50%) • 80% agreed that antimicrobal resistance is increasing70% believed resistant pathogens cause greater mortality

  7. Antimicrobial Resistance:A Global Problem

  8. Rates of Resistance Among Nosocomial Infections Reported in Intensive Care Patients, Comparison of 1999 (January-July) with Historical Data January-July 1999 1993-1998

  9. Percentage of ResistanceKFSH&RC Jeddah

  10. Emerging Pathogens • Methicillin-resistant Staphylococcus aureus (MRSA) • Methicillin-resistant Staphylococcus epidermitis (MRSE) • Vancomycin-resistant enterococci (VRE) • Vancomycin-intermediate Staphylococcus aureus (VISA) • Extended-spectrum beta-lactamase (ESBL)-producing gram-negative organisms • Multidrug-resistant Acinetobacter spp.

  11. Percentage of Nosocomial Staphylococcus aureus Reported as Resistant to Methicillin, by year National Nosocomial Infections Surveillance (NNIS), 1989-1998: system Data

  12. Methicillin Resistant Staphylococci by setting Fridkin. Clin Infect Dis.1999

  13. Secular Trend in MRSA InfectionsINSPEAR, 1990-1997 International Network for Surveillance and Prevention of Emerging Antimicrobial Resistance (INSPEAR)

  14. Methicillin-Resistant Staphylococcus aureus:Current Status • Endemic beginning 1980 in hospitals • Increasing reports of community infections: • Pediatric outpatients in Chicago • Alaskan natives • 4 Pediatric deaths: MMWR 1998

  15. Epidemiology of VRE • Present in all 50 states in the United States • Number of isolated continues to grow • Recognized in Europe, Japan, Central and South America • Resistance to alternate antibiotic therapy continues to be a problem

  16. Progression of Vancomycin Resistance Enterococci Mortone. WJ. Infect Control Hosp Epidemiol. 1998 NNIS Antimicrobial Resistance Surveillance Report 1999

  17. Risk Factors for VRE • Prior broad spectrum antibiotics (especially cephalosporins and vancomycin) • Prolonged hospitalization • Immunocompromised host • Neutropenia • Admission to an intensive care unit • Renal failure requiring dialysis Noskin. J Lab Clin Med. 1997

  18. Antibiotics and Colonization with VRE Ostrowsky. Arch Intern Med. 1999

  19. Use of Vancomycin in US and Rate of VRE Kirsl et al. Historical usage of vancomycin. Antimicrob Agent Chemo 1998 National Nosocomial Infection Surveillance System (CDC)

  20. Independent Predictors of Vancomycin-Resistant Enterococci in Adult Intensive Care Units NNIS

  21. Enterococcal Resistance by Species Jones. Diagn. Microbiol Infect Dis. 1998

  22. Outcome of Enterococcus faecium Bacteremia Stosor. Arch Intern Med. 1998

  23. Impact of Formulary Change on VREEmpiric therapy for febrile neutropenia Lisgaris. IDSA (abstract). 2000

  24. Prevention of GRETherapy for Febrile Neutropenia • Purpose: reduce glycopeptide resistant enterococci (GRE) • Situation: 50% colonization rate in oncology units • Methods: • Phase 1: no intervention (ceftazidime) • Phase 2a and 2b: replace ceftazidime with piperacillin/tazobactam • Phase 3: return to ceftazidime Bradley. JAC. 1999

  25. Results Phase 1 vs 2b (P<0.001) Bradley. JAC. 1999

  26. Impact of CDC Guidelines on Endemic VRE M. Montecalvo et al. Ann Int Med. 1999 J Morris et al. Ann Int Med. 1995 E Jochimsen et al. ICHE 1999

  27. Emergence of Vancmycin-Intermediate Staphylococcus aureus (VISA) in the World • First episode reported in Japan, 1996 • Predicted risk factors: • MRSA colonization/infection • Frequent/sustained vancomycin exposure • Predicted high risk population • ESRD on hemodialysis • Long-term CVCs • Rehab/skilled nursing facility patients • Prolonged ICU stay

  28. Extended Spectrum -lactamasesESBLs • 1983: first reported in Europe • 1988:: reported in the United States • 1990’s: increased prevalence globally: • ICU’s • Acute care • Extended care • 2000: Problematic nosocomial pathogen

  29. Extended Spectrum -lactamasesESBLs • ESBL inactivates oxyamino beta-lactams and fourth-generation cephalosporins (to some extent) and aztreonam • Large plasmids encoding multiple antibiotic resistance determinants including aminoglycoside modifying enzymes • Strains producing ESBL are typically sensitive to cephamycins and carbapenems • Common ESBL-producers: K. pneumoniae, and less common other Enterobactericae

  30. Klebsiella pneumoniaeResistance to third-generation cephalosporinsCDC Fridkin and Gaynes. Clin Chest Med. 1999

  31. K. pneumoniae Resistant to Extended-Spectrum -lactam (ESBL) at NNISEvidence of Inter-hospital Transmission Mannel DL, et al. Infect Control Hosp Epidemiolo 1997

  32. Emergence of Carbapenem-resistant Acinetobacter spp. • Frequent use of aminoglycosides, fluroquinolones, ureidopenicillins and third generation cephalosporins • Reported from South America, Europe, Far East, Middle East, and United States • Numerous outbreaks (some strains susceptible only to polymyxin B) • High mortality rates • Endemic in some hospitals

  33. Endemic Carbapenem-Resistant Acinetobacter spp. In Brooklyn, New York • 15 hospitals • November 1997, all aerobic bacteria collected • Acinetobacter spp. (233) accounted for 10% of the gram negative bacilli • Carbapenem resistance ranged from 0-100% • 10% of isolated were susceptible only to polymyxin • Risk factors • Use of third generation cephalosporins plus aztreonam • Environment and healthcare worker hands contamination documented • PFGE documented inter- and intra-hospital spread VM Manikal et al. CID. 2000

  34. Antimicrobial Susceptibility of 233 Acinetobacter spp., 15 Hospital, Brooklyn, New York VM Manikal et al. CID. 2000

  35. Control Measures • Barrier precautions • Oxyamino beta-lactam restriction • Selective bowel decontamination

  36. Antimicrobial Utilization and Resistance • Interdisciplinary team in Indianapolis to control resistant organisms • Interventions: • Reduce third generation cephalosporin use • Reduce imipenem use • Encourage use of ampicillin/sulbactam and piperacillin/tazobactam • Enhance compliance with infection control • Education regarding antimicrobial resistance

  37. Antimicrobial Utilization and Resistance Piperacillin/tazobactam resistant Smith. Pharmacotherapy 1999

  38. Impact of Formulary Changes on MRSA and Ceftazidime Resistant K. Pneumoniae • Reduce usage of cephalosporins, imipenem, clindamycin and vancomycin • Increased use of -lactam/-lactamase inhibitors Landman. Clin. Infect Dis. 1999

  39. Ceftazidime Resistant K. pneumoniaeCleveland VA Medical Center

  40. Cephalosporin Use and ESBL KP in ICUsIndianapolis VA

  41. Impact of a Rotating Empiric Antibiotic Schedule on Infectious Mortality in an Intensive Care Unit Raymond DP. Crit Care Med 01-Jun-2001, 29(6);1101-8

  42. Impact of a Rotating Empiric Antibiotic Schedule on Infectious Mortality in an Intensive Care Unit Raymond DP. Crit Care Med 01-Jun-2001, 29(6);1101-8

  43. Conclusion • Epidemiology of resistance in gram-negative and gram-positive organisms is complex, and is influenced, in part, by selective antimicrobial pressure • Control measures for emerging resistance include: • Traditional infection control measures: contact isolation

  44. ConclusionJudicious Use of Antimicrobial • Decrease cephalosporin use • Increase extended-spectrum penicillin/beta-lactamase inhibitor use • Limit carbapenem and vancomycin use to desired therapy

  45. Handwashing compared to Alcohol Hand

More Related